$3.24
13.29% today
Nasdaq, Feb 28, 04:52 pm CET
ISIN
US45256X1037
Symbol
IBRX
Sector
Industry

ImmunityBio Inc Stock price

$2.86
-0.27 8.63% 1M
-1.33 31.74% 6M
+0.30 11.72% YTD
-1.73 37.69% 1Y
-3.98 58.19% 3Y
-1.82 38.89% 5Y
-31.78 91.74% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.14 4.67%
ISIN
US45256X1037
Symbol
IBRX
Sector
Industry

Key metrics

Market capitalization $2.09b
Enterprise Value $2.98b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 406.22
P/S ratio (TTM) P/S ratio 284.89
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 1,218.71%
Revenue (TTM) Revenue $7.33m
EBIT (operating result TTM) EBIT $-359.29m
Free Cash Flow (TTM) Free Cash Flow $-434.10m
Cash position $130.37m
EPS (TTM) EPS $-0.89
P/E forward negative
P/S forward 98.33
EV/Sales forward 140.21
Short interest 28.68%
Show more

Is ImmunityBio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

ImmunityBio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a ImmunityBio Inc forecast:

3x Buy
75%
1x Hold
25%

Analyst Opinions

4 Analysts have issued a ImmunityBio Inc forecast:

Buy
75%
Hold
25%

Financial data from ImmunityBio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
7.33 7.33
1,209% 1,209%
100%
- Direct Costs 18 18
25% 25%
245%
-11 -11
55% 55%
-145%
- Selling and Administrative Expenses 126 126
55% 55%
1,722%
- Research and Development Expense 204 204
12% 12%
2,789%
-341 -341
1% 1%
-4,656%
- Depreciation and Amortization 18 18
25% 25%
245%
EBIT (Operating Income) EBIT -359 -359
0% 0%
-4,902%
Net Profit -588 -588
28% 28%
-8,019%

In millions USD.

Don't miss a Thing! We will send you all news about ImmunityBio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ImmunityBio Inc Stock News

Neutral
GlobeNewsWire
about 14 hours ago
NEW YORK , Feb. 27, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of long-term stockholders following a class action complaint that was filed against ImmunityBio on August 29, 2023 with a Class Period from May 23, 2022 to May 10, 2023. Our investigati...
Neutral
Business Wire
about 16 hours ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for ANKTIVA® and CAR-NK (PD-L1 t-haNK) for the reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Multiply Relapsed L...
Neutral
Business Wire
9 days ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) that will bring a vital alternative source of BCG, a standard-of-care medicine in bladder cancer, to patients in the U.S. Supply shortages of TICE® BCG in the U.S. have become a signif...
More ImmunityBio Inc News

Company Profile

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA.

Head office United States
CEO Richard Adcock
Employees 628
Founded 2014
Website www.immunitybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today